Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience.
The treatment results of 37 patients with malignant brain neoplasms treated with a computed-tomography-guided stereotactic iridium-192 implant are reviewed. Of these, 29 patients with high-grade gliomas (20 with glioblastoma multiforme (GBM), nine with anaplastic astrocytoma (AA] received an implant as part of their initial management. The median survival was 14.5 and 15.5 months in the patients with previously untreated GBM and AA, respectively. In those patients with recurrent tumour after external-beam irradiation, durable local control over a year was achieved with implantation. Increasing the total tumour dose from 120 to 160 Gy did not improve survival or local control. Karnofsky Performance Status (KPS) was used as an indicator of quality of life and was seen to decrease with a median interval of 8.5 months following treatment. No severe complications were noted in the entire group of patients treated with this implant procedure.
Chun
M
M
Department of Radiation Oncology, New England Medical Center Hospitals Boston, Massachusetts 02111.
McKeough
P
P
Wu
A
A
Kasdon
D
D
Heros
D
D
Chang
H
H
D000328:Adult; D001254:Astrocytoma / Q000401:mortality / Q000532:radiotherapy*; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D005909:Glioblastoma / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D007496:Iridium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011788:Quality of Life; D011879:Radiotherapy Dosage
D007496:Iridium Radioisotopes